The estimated Net Worth of John Y Caloz is at least 579 千$ dollars as of 22 February 2012. Mr. Caloz owns over 31,792 units of LadRx Corp stock worth over 2,861$ and over the last 17 years he sold CYTR stock worth over 0$. In addition, he makes 576,300$ as Chief Financial Officer、 Chief Accounting Officer、 IR Contact Officer at LadRx Corp.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Caloz CYTR stock SEC Form 4 insiders trading
John has made over 1 trades of the LadRx Corp stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 31,792 units of CYTR stock worth 10,173$ on 22 February 2012.
The largest trade he's ever made was buying 31,792 units of LadRx Corp stock on 22 February 2012 worth over 10,173$. On average, John trades about 1,987 units every 0 days since 2007. As of 22 February 2012 he still owns at least 31,792 units of LadRx Corp stock.
You can see the complete history of Mr. Caloz stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Caloz biography
John Y. Caloz was Chief Financial Officer, Chief Accounting Officer of the Company. Mr. Caloz was named Chief Financial Officer. He was Chief Accounting Officer of the company. He has a history of providing senior financial leadership in the life sciences sector, as Chief Financial Officer of Occulogix, Inc, a NASDAQ listed, medical therapy company. Prior to that, Mr. Caloz served as Chief Financial Officer of IRIS International Inc., a Chatsworth, CA based medical device manufacturer. He served as Chief Financial Officer of San Francisco-based Synarc, Inc., a medical imaging company, and from 1993 to 1999 he was Senior Vice President, Finance and Chief Financial Officer of Phoenix International Life Sciences Inc. of Montreal, Canada, which was acquired by MDS Inc. in 1999. Mr. Caloz was a partner at Rooney, Greig, Whitrod, Filion & Associates of Saint Laurent, Quebec, Canada, a firm of Chartered Accountants specializing in research and development and high tech companies, from 1983 to 1993. Mr. Caloz, a Chartered Professional Accountant and Chartered Accountant, holds a degree in Accounting from York University, Toronto, Canada.
What is the salary of John Caloz?
As the Chief Financial Officer、 Chief Accounting Officer、 IR Contact Officer of LadRx Corp, the total compensation of John Caloz at LadRx Corp is 576,300$. There are 2 executives at LadRx Corp getting paid more, with Steven Kriegsman having the highest compensation of 1,707,700$.
How old is John Caloz?
John Caloz is 64, he's been the Chief Financial Officer、 Chief Accounting Officer、 IR Contact Officer of LadRx Corp since 2020. There are 5 older and 3 younger executives at LadRx Corp. The oldest executive at LadRx Corp is Louis Ignarro, 79, who is the Independent Director.
What's John Caloz's mailing address?
John's mailing address filed with the SEC is 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES, CA, 90049.
Insiders trading at LadRx Corp
Over the last 21 years, insiders at LadRx Corp have traded over 0$ worth of LadRx Corp stock and bought 3,710,406 units worth 8,711,088$ . The most active insiders traders include Steven A Kriegsman、Scott Bradford Patterson、Max Link. On average, LadRx Corp executives and independent directors trade stock every 177 days with the average trade being worth of 22,531$. The most recent stock trade was executed by Earl W Brien on 14 August 2020, trading 150,000 units of CYTR stock currently worth 39,000$.
What does LadRx Corp's logo look like?
Complete history of Mr. Caloz stock trades at LadRx Corp
LadRx Corp executives and stock owners
LadRx Corp executives and other stock owners filed with the SEC include:
-
Steven Kriegsman,
Chairman of the Board, Chief Executive Officer -
Steven A. Kriegsman,
Chief Exec. Officer -
John Caloz,
Chief Financial Officer, Chief Accounting Officer, IR Contact Officer -
John Y. Caloz,
CFO, Treasurer & Sr. VP -
Louis Ignarro,
Independent Director -
Joel Caldwell,
Director -
Earl Brien,
Director -
Dr. Felix Kratz Ph.D.,
Sr. VP, Drug Devel. -
Cristina Newman,
Corp. Sec. -
Terri Stevens,
Chief Bus. Officer -
Molly Painter,
Pres of USA and Head of Launch & Commercial Operations -
Molly Carey Poarch,
Global & U.S. Head of Corp. Communications -
Jennifer K. Simpson,
Director -
Anita J Chawla,
Director -
Daniel J Levitt,
Chief Medical Officer -
Joseph Rubinfeld,
Director -
Olivia C Ware,
Chief Commercial Officer -
Douglas Scott Wieland,
Sr. VP - Drug Development -
Felix Kratz,
Vice President Drug Discovery -
Herbert H Jr Mcdade,
-
Alexander L Cappello,
Director -
Raymond C Jr Carnahan,
-
Ben Levin,
Gen.Cnsl/VP Legal Affairs/Secy -
Eric Jay Selter,
Director -
Cheryl Cohen,
Director -
Scott Bradford Patterson,
10% owner -
Marvin R Selter,
Director -
Richard J Wennekamp,
Director -
Max Link,
Director -
David Scott Geyer,
Sr. V.P. of Manufacturing -
Mitchell K Fogelman,
Chief Financial Officer -
Jack R Barber,
Sr VP - Drug Development -
Shi Chung Ng,
Sr. VP Research & Development -
Matt Natalizio,
Chief Financial Officer -
Mark Tepper,
Vice President -
Stephen Snowdy,
Chief Executive Officer